Alrestatin is a specific inhibitor of the aldose reductase enzyme.

Epalrestat (formerly also named ONO-2235) is a novel and potent aldose reductase inhibitor used for the treatment of diabetic neuropathy.

Tolrestat (AY27773) is a novel, potent, orally bioactive aldose reductase inhibitor with IC50 of 35 nM.

AT-007 is a novel and orally bioactive central nervous system (CNS) penetrant Aldose Reductase inhibitor for treatment of Galactosemia with an IC50 value of 100 pM.

Poliumoside possesses significant antiinflammatory and antioxidant activity, It is a novel and potent natural compound and is isolated from Brandisia hancei stems and leaves.

Ponalrestat (MK-538; ICI 128436; Statil) is a novel and potent aldose reductase inhibitor which inhibits the conversion of glucose to sorbitol.

Lidorestat (EML-676; ALN-101; IDD-000676-01; IDD-676) is a novel and potent aldose reductase inhibitor which is orally bioactive and can be used to treat chronic diabetes complications. It inhibits aldose reductase with an IC50 of 5 nM.

Isoliquiritigenin (also known as ISL; GU17; Isoliquiritigen) is a naturally occuring chalcone compound and NLRP3 antagonist found in licorice root and several other plants that displays antioxidant, anti-inflammatory, and antitumor activities as well as hepatoprotection against steatosis-induced oxidative stress.

Zopolrestat (CP-73850; CP73850) is a novel and potent aldose reductase inhibitor (IC50 = 3.1 nM) with the potential for the treatment of diabetic nephropathy and diabetes.

Ranirestat (AS-3201; SX-3201) is a novel, oral and potent aldose reductase inhibitor with the potential for the treatment of diabetic neuropathy.